VIVUS (VVUS) Is Today's Top Performing Wall Street Upgrade
Tweet
Share
E-mail
Get Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 24 | New: 9
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 24 | New: 9
Join SI Premium – FREE
With a 5 percent upside move, VIVUS Inc. (Nasdaq: VVUS) is the top performing Wall Street upgrade today, according to data tracked at StreetInsider.com's Ratings Central.
Canaccord Genuity upgraded shares of the obesity drug maker from Hold to Buy following data from the SEQUEL study which strengthens the case for Qnexa approval.
The firm also lifted their price target from $6 to $10, which still represents 43 percent upside from current levels.
"There is a high likelihood that the FDA will approve VVUS' obesity drug Qnexa based on the overall risk/benefit profile of the drug (supported by yesterday’s two-year study results)," according to Canaccord Genuity analyst Adam Cutler. "While we think a delay beyond the Oct. 28 PDUFA date is very possible, we believe that approval in H1/11 would drive significant upside in the stock."
Canaccord Genuity upgraded shares of the obesity drug maker from Hold to Buy following data from the SEQUEL study which strengthens the case for Qnexa approval.
The firm also lifted their price target from $6 to $10, which still represents 43 percent upside from current levels.
"There is a high likelihood that the FDA will approve VVUS' obesity drug Qnexa based on the overall risk/benefit profile of the drug (supported by yesterday’s two-year study results)," according to Canaccord Genuity analyst Adam Cutler. "While we think a delay beyond the Oct. 28 PDUFA date is very possible, we believe that approval in H1/11 would drive significant upside in the stock."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Upgrades Mahanagar Gas Limited (MAHGL:IN) to Reduce (3)
- Entera Bio prices $275M private placement led by BVF Partners
- Entera Bio prices $275 million private placement led by BVF Partners
Create E-mail Alert Related Categories
Insiders' Blog, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
